[Effect of a complex treatment, including glutargin and erbisol on the blood plasma content of protein P53, apoptotic markers of type II, activity of caspases and the level of sCD 117 in patients with autonomic-vascular dystonia].
It has been established that the blood content of protein P53 diminishes by 27%, the blood level of sTRAIL increases by 22%, sCD 117 increases by 44% in patients with vegeto-vascular dystonia of the hypertonic type that is accompanied by an increase of the activity of caspases-1 however the activity of caspases-3 and - 8 as well as the blood content of TNF-alpha do not change. Multimodality therapy using glutargin does not influence on the level of the blood plasma TNF-alpha and the activity of caspases-1,-3,-8, normalizes the blood content of sTRAIL and sCD 117, however does not change the plasma concentration of protein P53 which remains lower by 35% than the control indices. In patients with vegeto-vascular dystonia of the hypotonic type the concentration of blood plasma protein P53, TNF-alpha and sTRAIL and the activity of caspases-1,-3,-8 correspond to the control values against a background of an almost twofold increase of the plasma sCD 117 level. The use of erbisol in a complex of therapeutic agents does not change the activity of caspases-l,-3,-8 and does not influence on the blood content of protein p53, TNF-alpha and sTRAIL and diminishes the plasma level of sCD 117 up to control values. A considerable elevation of the blood content of type II apoptotic factors is characteristic of the mixed type of vegeto-vascular dystonia: the level of protein p53 increases 2,4 times, TNF-alpha - 1,9 times, sTRAIL - 2,3 times that is accompanied by an increased activity of caspase-1 - 4,1 times, caspase-3 - 3,3 times, caspase-8 - 3,8 times and an increase of the plasma concentration of sCD 117 - 3,5 times. The use of erbisol and glutargin in multimodality therapy normalizes the plasma concentration of TNF-alpha and diminishes the blood content of protein P53 by 33% and sTRAIL - by 42% which, nevertheless remains higher than the control value by 58% and 36% respectively. The combined effects of glutargin and erbisol in patients of this group are characterized by a decrease (but not normalization) of the blood content of sCD 117 by 47% and more than twofold decrease of the activity of caspases-1,-3 and -8.
Krychun
I I
II
D000293:Adolescent; D000328:Adult; D017209:Apoptosis / Q000187:drug effects; D001342:Autonomic Nervous System Diseases / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D001685:Biological Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D020169:Caspases / Q000378:metabolism*; D002560:Cerebrovascular Circulation / Q000187:drug effects; D004151:Dipeptides / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy; D007022:Hypotension / Q000097:blood / Q000150:complications / Q000188:drug therapy; D008297:Male; D019009:Proto-Oncogene Proteins c-kit / Q000097:blood*; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000097:blood; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D016159:Tumor Suppressor Protein p53 / Q000097:blood*; D014652:Vascular Diseases / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D055815:Young Adult
D001685:Biological Factors; D015415:Biomarkers; D004151:Dipeptides; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; D014409:Tumor Necrosis Factor-alpha; D016159:Tumor Suppressor Protein p53; C096287:erbisol; D019009:Proto-Oncogene Proteins c-kit; D020169:Caspases; C024362:arginine glutamate